Skip to main content
. 2023 Oct 24;65:102270. doi: 10.1016/j.eclinm.2023.102270

Fig. 4.

Fig. 4

IPES performance on predicting OS risk of stage I and II-III resected NSCLC patients with EGFR mutation or EGFR wild-type status. (a) and (b) Kaplan–Meier curves of the low- and high-risk subgroups predicted by IPES for resected NSCLC patients with EGFR mutation in (a) stage I and (b) stage II-III in the internal validation set. (c) and (d) Kaplan–Meier curves of the low- and high-risk subgroups predicted by IPES for resected NSCLC patients with EGFR wild-type status in (c) stage I and (d) stage II-III in the internal validation set. In the Kaplan–Meier curves, the horizontal axis represents survival time (months) and the vertical axis represents survival probability.